Duffy Sean P. sold $510K of OMDA

Duffy Sean P. (Chief Executive Officer) sold 21,570 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($20.90–$24.81, $0.51M total) across 3 trades over 2026-08-07 to 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duffy Sean P.
Published Aug 11, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
medium confidence
Mentioned
$OMDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The only new fact is the disclosed sale size, timing (Aug 7 to Aug 10), and post-transaction holdings (411,861 shares). There is no new company-specific fundamental information in the text.

02

Market read

Traders may treat this as a minor sentiment datapoint, but it is unlikely to drive a durable repricing without additional fundamental catalysts.

03

What to watch

The filing does not state reasons for the sale, and the price range ($20.90 to $24.81) spans multiple days, limiting inference about timing or valuation views.

Relevance 4/10Novelty 3/10Timing: filed Aug 11, covering sales from Aug 7 to Aug 10

Background

This is an SEC Form 4 insider transaction by Omada Health CEO Sean P. Duffy, reporting open-market sales under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$OMDANeutralMedium confidence
Context

Omada Health CEO Sean P. Duffy sold about $509.6K of OMDA shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

Form 4 shows a planned sale (10b5-1) with no accompanying guidance, deal, or regulatory event; insider selling can still be read as signal, but the pre-arranged nature reduces interpretive weight.

Market effects

No direct sector read-through beyond routine insider activity in digital health.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; the disclosure may not reflect new negative information.

Key entities

  • Omada Health, Inc.

    Subject of the Form 4 insider transaction; CEO Sean P. Duffy sold shares totaling about $509.6K.

  • Sean P. Duffy

    CEO and officer/director who executed the open-market sales under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.